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Purpose: It was hypothesized that tear protein biomarkers could predict the effects of topical steroid
treatment and desiccating stress in patients with dry eye disease (DED). To test this concept, a ran-
domized, double-masked, controlled clinical trial with 41 patients was conducted.
Methods: The patients were treated topically with either 0.1% ﬂuorometholone (FML) or polyvinyl
alcohol (PA). Tear samples were collected using 1 ml glass capillaries at recruitment into the study and
after a 3-week treatment period, both before and after 2 h exposure to desiccating stress, in a controlled
environment chamber. Relative quantiﬁcation of tear proteins was conducted by NanoLC-MSTOF using
sequential window acquisition of all theoretical mass spectra (SWATH). Ocular surface integrity (corneal
and conjunctival staining and conjunctival hyperemia) was selected as the key DED-related sign and
analyzed with proteomic data. Analysis of covariance (ANCOVA) and linear models were used to analyze
the data with R.
Results: 758 proteins were identiﬁed and relatively quantiﬁed from each tear sample. Analysis revealed 9
differentially expressed proteins between FML and PA treatments after 3 weeks and 7 after desiccating
stress (P < 0.05). We also identiﬁed several differentially expressed proteins at the initial collection,
which could be used to predict changes of conjunctival and corneal staining and conjunctival hyperemia
after FML treatment and after desiccating stress. These proteins include complement C3 (C3) and
calmodulin like 5 (CALML5), which could also differentiate the severity of DED at baseline.
Conclusions: The identiﬁed proteins could be further used as biomarkers to identify patients most
beneﬁting from FML treatment.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).yliopisto, Finland.
).
Inc. This is an open access article u1. Introduction
Tear ﬂuid is a complex, extra-cellular ﬂuid from various secre-
tory sources, including the lacrimal glands, cornea, conjunctival
cells and blood ultra-ﬁltrates [1]. Tears bathe the ocular surface asnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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anterior surface of the eye, improve the retinal image, and
contribute to the mechanical, antimicrobial and anti-inﬂammatory
defense of the ocular surface [2,3]. Any dysfunction in tear ﬂow,
production or composition can cause adverse effects to the health
of the ocular surface and the visual process.
Dry eye disease (DED) is an immune-based multifactorial dis-
ease of the ocular surface resulting from a dysfunction of the
lacrimal functional unit, which maintains a homeostatic environ-
ment of the ocular surface [4e6]. Management of DED usually be-
gins with artiﬁcial tears, whichmainly increase the aqueous layer of
the tear ﬁlm and may dilute inﬂammatory cytokines, which are
upregulated in DED [6,7]. In more severe DED, topical steroids or
other anti-inﬂammatory medications such as topical cyclosporine
are commonly used [6,8]. Several studies have shown that corti-
costeroids suppress the expression of tumor necrosis factor-alpha
(TNF-a), mitogen-activated protein kinase (MAPK) and nuclear
factor-kappaB (NF-kB) pathways [9e11]. They have been demon-
strated to be effective, in particular during and after desiccating
stress, but are used with caution in long-term treatment due to
adverse side effects [8,12].
The present study continues from a publication by Pinto-Fraga
et al. (2016) revealing the positive action of topical 0.1% ﬂuo-
rometholone (FML) in DED patients in adverse environments in
comparison to polyvinyl alcohol vehicle (PA) treatment [13].
Conjunctival hyperemia as well as corneal and conjunctival staining
were signiﬁcantly decreased in patients with FML treatment in
comparison to vehicle, PA. In our study, tear samples collected from
these patients were used for proteomics analysis. The hypothesis of
the current study was that topical FML treatment would beneﬁt the
patients, ameliorating the desiccating stress effects, and that this
would be reﬂected in changes of the tear proteome. Additionally,
another aim was to identify proteins speciﬁcally indicating and
predicting the treatment effects combined with desiccating stress.Fig. 1. Flowchart of the study workﬂow. The 22-day study period included 4 visits (V) t
perature and localized airﬂow were controlled. DED patients were recruited in baseline (V
alcohol (PA), four times per day for 21 days, i.e. 3 weeks (V2). Immediately after V2 patients
which the patients still took their assigned topical medication, the study was concluded (V4)
exposures to either NCE or ACE.2. Methods
2.1. Study outline
The study was a single randomized, double-masked, vehicle-
controlled, parallel-group, phase 3 clinical trial (clinicaltrials.gov:
identiﬁer NCT0205102313) with 41 patients who had been previ-
ously diagnosed with either moderate or severe DED. This clinical
trial was fully approved by an Ethics Committee and followed the
tenets of the Declaration of Helsinki. Informed consent was ob-
tained from the subjects after explanation of the nature and
possible consequences of the study.
As shown in Fig. 1, the clinical trial was conducted during a 22-
day period during which DED patients underwent 4 visits in the
environmental chamber within the Controlled Environmental
Research Laboratory (CERLab, Instituto Universitario de Oftalmo-
biología Aplicada, University of Valladolid) [14,15]. Clinical infor-
mation and tear samples were collected from the patients during
each visit [13]. Clinical examinations included ﬂuorescein corneal
staining, lissamine green conjunctival staining, and slit-lamp bio-
microscopy, among others. Clinical examinations were conducted
on both eyes and a randomly chosen eye was used in this study,
along with tear samples from the same eye.
2.2. Tear collection
Unstimulated tear samples were collected from one eye of all 41
DED patients using 1 ml Microcap® tubes (Drummond, Broomall, PA,
USA) from the open eye [14,15], avoiding tissue contact to prevent
reﬂex tearing. Tear collection was the ﬁrst test performed in order
to avoid any inﬂuence from other tests. Samples were immediately
transferred to storage tubes at 80 C until processed.
2.3. Chemicals and materials
Acetonitrile (ACN), formic acid (FA), water (UHPLC-MS grade),o the environmental chamber with either NCE or ACE, where relative humidity, tem-
1) and randomized to use either 0.1% ﬂuorometholone (FML) or its vehicle, polyvinyl
were exposed to desiccating stress for 2 h (V3). After one day (24 h) recovery, during
. Tear capillary samples were collected from patients during each visit (V1-V4) after the
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sulfate (SDS), iodoacetamide (IAA), triﬂuoroacetic acid (TFA),
ammonium bicarbonate (ABC) and urea were all purchased from
Sigma Aldrich (St. Louis, MO, USA). Halt™ Protease Inhibitor
Cocktail and sample clean up tips (C18) were from Thermo Fisher
Scientiﬁc (San Jose, CA, USA). Bio-Rad DC™ kit and bovine serum
albumin standard were purchased from Bio-Rad (Hercules, CA,
USA) and 30 kDa molecular weight cut off (MWCO) centrifugal
devices from PALL (Port Washington, NY, USA). Retention time
calibration peptides (Hyper reaction monitoring (HRM) Calibration
Kit) were purchased from Biognosys AG (Zurich, Switzerland).2.4. Sample preparation and analysis
Tear samples were dissolved from capillary tubes in 0.5% SDS,
50 mM ABC, HALT™ protease inhibitor, incubated on ice for 60 min
and centrifuged with low rpm to avoid the breaking of the capil-
laries (3000 rpm, 2 min). Protein concentration was measured us-
ing Bio-Rad DC protein quantiﬁcation kit. Average amount of
protein recovered per sample was 20 ± 9 mg (SD). The smallest
amount taken to tryptic digestion was 6 mg of total protein. Seven
patients had less than 6 mg of protein in the tear samples and were
therefore not analyzed further. Two additional patients were
excluded from the study for other reasons.
Samples were then subjected to reduction, alkylation, and
tryptic digestion. These steps were performed according to the
description in the supplementary method materials. For mass
spectrometry, analysis samples were eluted to the same concen-
tration and 2.6 mg of sample was injected into NanoLC-TripleTOF
(Sciex 5600). Two technical replicates were produced from each
sample. Analysis of the samples was done by NanoLC-TripleTOF
mass spectrometry using SWATH acquisition as described in the
supplementary method material.2.5. Protein identiﬁcation and quantiﬁcation
As part of the SWATH analysis method, a relative protein
quantiﬁcation library, consisting of >870 tear proteins, was created
using tear samples from this study and from another clinical study
consisting of glaucoma patients and their controls. Overall library
consisted of 37 different patients/samples and 64 data- dependent
analysis (DDA) runs with same LC gradient and instrument settings,
whichwere used for SWATH analyses. The library was created using
Protein Pilot® 4.5 (Sciex, Redwood City, USA) and all DDA runs
spectra were identiﬁed against UniprotKB/SwissProt. Quantiﬁca-
tion was done by Peak Viewer® and Marker viewer® (Sciex, Red-
wood City, USA). FDR 1% was used in the library creation and only
distinctive peptides were used in the quantiﬁcation. Retention time
calibration was done for all samples using HMR retention time
calibration peptides. Five transitions per peptide and 1e15 peptides
were used for peak area calculations. All proteins with signiﬁcant or
interesting ﬁndings in the data analysis were subjected to manual
inspection of peptides. This consisted of checking correct peak se-
lection in the chromatogram (FDR 1%, 99% peptide conﬁdence
level), sufﬁcient signal to noise ratio inspection (>7) and chro-
matogram inspection in relation to library chromatogram. Also,
variation of technical replicate results were calculated as means to
all samples/protein. Peptides were eliminated from result pro-
cessing if manual inspection requirements were not fulﬁlled. Pro-
teins with missing values were excluded from consideration.
Results are presented as combination of protein-speciﬁc peptides
peak areas from SWATH mass spectrometry measurement and
referred to as protein expression.2.6. Data analysis
Data processing included log2-transformation and percentile
normalization in which the sample distributions were normalized
based on the global median. The quality of the technical replicates
was analyzed by analysing the intraclass correlation (ICC) and
Pearson correlation was used to generate p-values (P) in permu-
tation tests (n ¼ 1000 permutations/technical replicate). Means of
the dependent technical replicates were used for further analysis.
The treatment effect was analyzed using analysis of covariance
(ANCOVA) in order to evaluate the differences in protein levels at
each visit to control for protein expression in the previous visit. The
normality of residuals was tested using the Shapiro-Wilk normality
test and the homogeneity of variance was tested using the Bartlett
test of homogeneity of variances. Additional assumptions of
ANCOVA, i.e., the assumption of parallel slopes and independence
of covariate (previous visit) and independent variable (treatment
effect) were in addition tested accordingly. Post hoc analysis in
ANCOVA was conducted using pairwise Tukey tests on adjusted
means, using the multcomp package in R (R Core Team. Foundation
for Statistical Computing, Vienna, Austria). Protein associations for
given biological functions (inﬂammation) were identiﬁed in R
based on their UniProt (UniProt.ws) term and its offspring terms as
well as by using the associated terms provided by Ingenuity®
Pathway Analysis (IPA, QIAGEN Redwood City, USA).
Multiple linear regression was used to evaluate which proteins
were related to percentage changes in speciﬁc clinical signs. The
protein expression level of the previous visit and treatment effect
were accounted for as independent variables. The interaction terms
of treatment effect and the baseline levels of protein expression
were included in the model and were of main interest. The clinical
signs were evaluated in percentage changes as in the previously
published work as qualitative variables (1). The severity compari-
sons at baseline were conducted using Wilcoxon rank sum test.
if
8>>><
>>>:
Ypost >Ypre/DY ¼ Ypost  YpreYmax  Ypre*100
Ypost ¼ Ypre/DY ¼ 0
Ypost <Ypre/DY ¼ Ypost  YpreYpre  Ymin
*100
(1)
where Ymax ¼ maximum value; Ymin ¼ minimum value;
Ypre ¼ initial value; Ypost ¼ final value; DY ¼ percentage change.
Benjamini-Hochberg adjustment was applied to all initial p-
values (P) where applicable to account for the multiple testing is-
sues. The signiﬁcance threshold was chosen as alpha ¼ 0.05. R
software version 3.2.3 was used to analyze data. IPA was used to
conduct pathway analysis and identify proteins connected to in-
ﬂammatory pathways.
3. Results
Altogether, 758 proteins were identiﬁed and relatively quanti-
ﬁed from each 1 ml sample (32 patients, 128 samples). The SWATH
data consisted of reproducible results with a mean intraclass cor-
relation (ICC) coefﬁcient of 0.97 between technical replicates. Per-
mutation tests using Pearson correlation with the technical
replicates showed that 80% of the technical replicates had a
P < 0.05, which suggests that the technical replicates are of rela-
tively good quality. Two approaches were adopted to analyze the
proteomic data; the ﬁrst was to evaluate the effects of FML on the
tear proteome as such and after a desiccating stress at the planned
visits, and the secondwas the incorporation of the clinical signs and
their relationship to the proteomic data. The patient characteristics
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Appendix A (Tables A.1 and A.2).
3.1. FML treatment and desiccating stress effects on tear proteins
When the protein expression levels were examined, 9 proteins
were found to differ between FML and vehicle (PA) groups after 3-
week treatment period (adjusted model P < 0.05 and treatment
effect P < 0.05), and 7 proteins were differentially expressed in
these groups after desiccating stress (Table 1). Most of these pro-
teins were associated to inﬂammation according to the linked gene
ontology (GO) terms. In addition, similar tests were conducted for
the follow-up (V4) data but only one protein showed statistically
signiﬁcant changes between the groups. This was more speciﬁcally
Ig heavy chain V-I region V35 (P23083) (Baseline (P) < 0.001;
Treatment (P) ¼ 0.019; log2 ratio (post hoc) ¼ 0.52). The signiﬁ-
cant proteins were analyzed further to test ANCOVA assumptions,
and the results can be found in Appendix B (Table B.1).
3.2. Proinﬂammatory proteins and their connections to clinical
signs
The ability of the expressed proteins to predict subsequent
clinical sign changes was evaluated next. Ocular surface integrity
(corneal and conjunctival staining) and conjunctival hyperemia
were selected as the key DED-related signs since they showed
statistically signiﬁcant clinical changes in this patient group
(Appendix C, Table C.1).
Individual protein expression levels and treatment, FML or PA,
were used to predict the DED-related sign changes between initial
baseline and after the 3-week treatment period (V1-V2). Sixty-
eight potentially predictive proteins (model P (adj.) < 0.05 and
interaction term P < 0.05) were identiﬁed for conjunctival staining
change and 38 potentially predictive proteins for corneal staining
change. In addition, there were 28 proteins with potential con-
nections to the conjunctival hyperemia change between V1 and V2.
Appendix D (Tables D.1-4) shows the statistically signiﬁcant results.
Corneal and conjunctival staining change results had 7 proteins in
common: complement C3 (C3), ig mu chain C region (IGHM) and
14-3-3 protein sigma (SFN), calmodulin like 5 (CALML5), LIM and
SH3 domain protein 1 (LASP1), quinone oxidoreductase (CRYZ) andTable 1
Protein abundance difference between treatments (0.1% ﬂuorometholone (FML), polyvin
Time point UniProt Full name
After 3-week treatment period P63261b Actin, cytoplasmic 2
P08758b Annexin A5
P00751a,b Complement factor B
P01042a,b Kininogen-1
P01743 Ig heavy chain V-I region HG3
P02511b Alpha-crystallin B chain
P11766b Alcohol dehydrogenase class-3
P47755 F-actin-capping protein subunit alpha-2
P18827a,b Syndecan-1
After desiccating stress P98160b Basement membrane-speciﬁc heparan sulfa
proteoglycan core protein
P00558b Phosphoglycerate kinase 1
P06744b Glucose-6-phosphate isomerase
P20061b Transcobalamin-1
P10599b Thioredoxin
Q13510 Acid ceramidase
P04746b Pancreatic alpha-amylase
Positive log2 ratio values (bold) indicate higher protein expression in FML than PA and n
a Proteins connected to inﬂammation based on UniProt accession.
b Connections to inﬂammation based on Ingenuity® Pathway Analysis (IPA).proline-rich protein 4 (PRR4). CALML5 was also associated with
conjunctival hyperemia. C3, IGHM, SFN and LASP1 displayed similar
regression patterns in comparison to each other and similarly
CALML5, CRYZ and PRR4 behave similarly according to the data.
All statistically signiﬁcant proteins were analyzed further by
pathway analysis (IPA). The top results are listed in Appendix E
(Table E.1), indicating that many identiﬁed proteins are connected
to apoptosis-, migration- and inﬂammation-related pathways.
Three inﬂammation-associated proteins common for corneal and
conjunctival staining (C3, IGHM and SFN) and CALML5 were
examined in more detail (Fig. 2). These proteins were further found
to be connected to proinﬂammatory cytokines and NF-kB
(Appendix E, Fig. E.1). The analysis showed that FML-treated pa-
tients with low initial baseline expression levels in C3, IGHM and
SFN and high baseline expression of CALML5 were more likely to
exhibit greater improvement in staining scores compared to pa-
tients with higher initial expression levels. Alternatively, FML-
treated patients with low CALML5 expression and/or high C3,
IGHM and SFN expression in the baseline appear to be less likely to
have a great improvement in their clinical signs (Fig. 2). PA treat-
ment of DED patients had little effect on corneal or conjunctival
staining and the protein baseline expression levels but higher
CALML5 expression in the baseline predicted worsening of
conjunctival hyperemia.3.3. DED severity differences on baseline protein expression
The relationship of CALML5, C3, IGHM and SFN baseline
expression levels and the DED severity status, i.e., moderate or
severe, was examined next. Expression differences of CALML5 and
C3 were signiﬁcantly different in moderate and severe patients
(P ¼ 0.002 and P ¼ 0.009 respectively) (Fig. 3). In severe DED pa-
tients CALML5 was downregulated (log2 fold change of 0.79) and
C3 was upregulated (log2 fold change 0.93). The correlation
(Spearman's rank correlation) between C3 and CALML5 baseline
expression levels was negative and statistically signiﬁcant
(rho ¼ 0.5, P ¼ 0.004), which indicates that these proteins are
connected suggesting that they could be used as predictivemarkers
for DED severity at baseline.yl alcohol (PA)) after 3-week treatment period and after desiccating stress.
Gene name Baseline (P) Treatment (P) Model (P) Model (Adj. P) Log2 ratio
ACTG1 <0.001 0.029 <0.001 <0.001 0.552
ANXA5 <0.001 0.009 <0.001 0.001 0.567
CFB <0.001 0.046 <0.001 <0.001 0.485
KNG1 <0.001 0.005 <0.001 <0.001 0.891
0.001 0.040 0.002 0.013 0.452
CRYAB 0.019 0.040 0.013 0.050 1.206
ADH5 0.230 0.028 0.010 0.043 0.773
CAPZA2 0.008 0.048 0.009 0.040 0.595
SDC1 0.114 0.007 0.012 0.049 1.322
te HSPG2 <0.001 0.050 <0.001 <0.001 0.281
PGK1 0.01 0.046 0.007 0.035 0.496
GPI <0.001 0.039 <0.001 0.002 0.578
TCN1 <0.001 0.049 <0.001 <0.001 0.426
TXN <0.001 0.010 <0.001 <0.001 0.767
ASAH1 <0.001 0.011 <0.001 0.002 0.767
AMY2A <0.001 0.030 <0.001 0.001 0.565
egative values lower expression in FML.
Fig. 2. Summary of the clinical sign changes during 3-week treatment and their connections to protein baseline expressions. A: Complement C3 (C3), ig mu chain C region
(IGHM) and 14-3-3 protein sigma (SFN) expression levels in the baseline (x-axis) can be used to predict the corneal and conjunctival staining change (%) (y-axis) in patients treated
with 0.1% ﬂuorometholone (FML). Treatments are ﬁtted by separate lines and each dot represents a patient. B: Calmodulin like 5 (CALML5) expression level in the baseline (x-axis)
could be used to predict corneal and conjunctival staining and conjunctival hyperemia change (%). C: The results for these four proteins for different treatments are summarized.
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on the treatment and protein expression
The clinical signs before and after the 2 h controlled adverse
environment exposure (V2-V3) were also analyzed in connection to
the proteomics data and 68 statistically signiﬁcant proteins were
associated with conjunctival staining change (%). Signiﬁcant pro-
teins found in V1-V2 and V2-V3 for conjunctival staining change
had 12 proteins in common and these included proteins related to
lacrimal gland (prolactin-inducible protein (PIP), lysozyme C (LYZ),
Proline-rich protein 4 (PRR4)), cystatins (cystatin-S (CST4),
cystatin-SN (CST1), cystatin-B (CSTB)), as well as alcohol dehydro-
genase class 4 mu/sigma chain (ADH7), 60S acidic ribosomal pro-
tein P2 (RPLP2), nucleobindin-2 (NUCB2), histone H1.4 (HIST1H1E),
secreted frizzled-related protein 1 (SFRP1). Fig. 4 shows some of
these results along with the severity of staining. Proteins unique to
only these results included alpha-enolase (ENO1), plasma serine
protease inhibitor (SERPINA5) and phospholipid transfer protein
(PLTP) which had similar patterns as CSTB but are not visualised
further here.
Patients receiving FML were not greatly affected by the protein
expression levels prior to the desiccating stress, but patients
receiving PAwere (Fig. 4A). For most proteins, excluding only CSTB,
lower expression levels prior to desiccating stress indicated greater
conjunctival staining. DED severity and protein expression levels
were again compared. At both visits, CST4 decreased with patients
with severe DED in comparison to moderate DED (P ¼ 0.025 andP ¼ 0.005 respectively) in baseline (log2 fold change ¼ 1.019) and
after 3-week treatment (log2 fold change ¼ 1.341) (Fig. 4B). In
addition, CST1 (log2 fold change ¼ 1.58, P ¼ 0.004), ADH7 (log2
fold change ¼ 0.573, P ¼ 0.033) and NUCB2 (log2 fold
change ¼ 0.832, P ¼ 0.024) were statistically signiﬁcant in pa-
tients after the 3-week treatment but were omitted from the vis-
ualisation for simplicity. There were no statistically signiﬁcant
proteins related to the desiccating stress effect (V2-V3) in corneal
staining or conjunctival hyperemia and no proteins were related to
clinical changes after the desiccating stress effect and follow-up,
i.e., V3-V4.
4. Discussion
The results of this study show that the tear proteome reﬂects the
biological status of the ocular surface and that DED and desiccating
stress change the proteome to amore inﬂammatory status, which is
remediated by steroid treatment. Two of the proteins upregulated
in FML-treated patients, ANXA5 and CRYAB, have been associated
with epithelial wound healing [16] and anti-inﬂammatory func-
tions via e.g. suppressing of NF-kB activation [17e21] while another
protein also upregulated in FML-treated patients, ACTG1, has been
associated with keratoconus [22]. In addition, FML treatment
downregulated CFB, KNG1, ADH5 and SDC1, which are all proin-
ﬂammatory proteins [23,24], acting most likely via NF-kB [25], as
well as through TNF-a and IFN-g [26]. These differentially
expressed proteins associated with FML treatment suggest that
Fig. 4. Summary of the clinical sign changes after desiccating stress and their connections to protein expressions prior to stress. A: Lysozyme C (LYZ), proline-rich protein 4
(PRR4), cystatin-S (CST4), prolactin-inducible protein (PIP), cystatin-SN (CST1) and cystatin-B (CSTB) expression levels after 3-week treatment (x-axis) can be used to predict the
conjunctival staining change (%) after the desiccating stress (y-axis) in patients treated with polyvinyl alcohol (PA). Treatments are ﬁtted by separate lines and each dot represents a
patient. B: CST4 separated patients based on severity at baseline and after the 3-week treatment period. C: The results from the analysis are summarized.
Fig. 3. Complement C3 (C3) and calmodulin like 5 (CALML5) baseline expression levels between different dry eye (DED) severity levels in baseline. Upregulation of C3 and
downregulation of CALML5 at baseline (y-axis) are associated with severe DED (x-axis). In the boxplots, the bottom and the top of the box are the ﬁrst and third quartiles
respectively and the horizontal line in the middle is the median. The vertical lines show the lowest and highest values still within 1.5 interquartile range (IQR) of the lower or upper
quartile and the points represent outliers. *P < 0.05.
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FML, possibly via NF-kB pathway. This is also supported by the
preceding clinical study [13]. Thus, the results of these studies
conﬁrm the anti-inﬂammatory properties of FML, a synthetic
glucocorticoid. FML is weaker than many other glucocorticoids e.g.,
prednisolone and dexamethasone, but, in particular with DED pa-
tients, it tends to lead to less pressure elevations than other steroids
commonly used to reduce inﬂammation [27,28]. These identiﬁed
proteins are potential biomarkers for FML-treatment and should be
examined further in future.
In desiccating stress, PGK1, GPI, and TXN, were signiﬁcantly
upregulated in FML-treated patients. These proteins have been
associated with proinﬂammatory functions in patients with rheu-
matoid arthritis [29e31], but the connections to the eye have not
been extensively studied. An FML-downregulated protein, HSPG2
has been connected to the barrier functions of the eye and cell
adhesion and it is potentially upregulated when IOP increases [32],
while another FML-downregulated protein, TCN1, has also been
shown to be downregulated in DED [33]. Based on these results,
cellular stress, likely due to the desiccating stress, appears to be
worse for FML-treated patients. Alternatively, the effects of the
stress may occur later for PA-treated patients and the process is
simply accelerated for FML-treated patients. In any case, no dif-
ferences at the ﬁnal 24 h post-stress visit, were observed. These
desiccating stress effects with FML-treated patients do require
further work, potentially with more time points, in order to better
understand the occurring changes.
Pinto-Fraga et al. (2016) [13], as well as our own analysis,
revealed that corneal and conjunctival staining and conjunctival
hyperemia improved during the 3-week FML treatment period, and
the effects of desiccating stress were reduced among moderate to
severe DED patients receiving FML treatment. Integrating prote-
omics data with the clinical signs suggested that initial baseline
protein expression levels could be used to predict the treatment
effect. Four proteins with predictive relationships were highlighted
in this study: CALML5, C3, IGHM and SFN.
CALML5 regulates barrier function proteins and terminal
epidermal differentiation genes, and it has been reported that a
knockout of CALML5 disrupts both of these biological functions
[34]. In our results, this proteinwas downregulated in patients with
a more severe DED condition, which could be explained by
disruption of barrier functions and epidermal differentiation. One
recently discovered interaction partner of CALML5 is SFN [34],
which was also identiﬁed as a protein of interest. SFN is an
epithelial cell speciﬁc, secreted 14-3-3 family protein and there is
evidence of ocular surface expression in the corneal and conjunc-
tival epithelium [35]. It has been shown that as CALML5 is depleted
in differentiated keratinocytes, many SFN interactors have altered
abundance, which suggests that CALML5 is in some way modu-
lating SFN. Therefore, our results, which suggest that both of these
proteins are signiﬁcant to FML-treatment effect prediction, seem
feasible based on previous studies.
C3 is well-known for its important role in the activation of
complement system, which has been previously connected to DED
[36]. Furthermore, C3 is increased in severe inﬂammatory diseases
[37] and primary Sj€ogren's syndrome onset was reduced in C3-gene
knockout mice [38]. IGHM, similar to C3, has been shown to be a
secreted tear protein [3] connected to the immune system. Both of
these proteins have a similar relationship to changes in clinical
signs as SFN, suggesting that the immune system and complement
cascade related proteins, such as C3 could be further used to
identify which patients would beneﬁt most from the FML treat-
ment. In addition, C3, similar to CALML5, does separate clinically
assigned severe and moderate patients from each other, and thesetwo proteins had a statistically signiﬁcant (negative) correlation,
which suggests that they could be connected to each other and
changed expression of either of the two, could indicate the severity
of DED of a given patient.
IPA pathway analysis showed that the four proteins associated
with FML-treatment prediction were connected to proin-
ﬂammatory cytokines and P38 MAPK, as well as phosphoinositide
3-kinase (PI3K) and NF-kB complexes, either directly or via, e.g.,
immunoglobulins and caspases. Proinﬂammatory cytokines are
some of the main targets of corticosteroids, and they are known to
also inhibit NF-kB [39,40], which is a transcription factor regulating
the synthesis of several proinﬂammatory proteins, and there is also
evidence that NF-kB-mediated pathways are activated in DED
related chronic graft-versus-host disease [41]. In addition, topical
modulation of NF-kB activation leads to improvement of clinical
markers of DED in mice exposed to desiccating stress [42]. The
effects of FML could therefore explainwhy these proteins, andmore
speciﬁcally their initial baseline expression levels, would provide
usmore information as to how patients will react to FML treatment.
Similarly to the treatment effects, the severity and individual
protein expression levels mattered during the desiccating stress,
but only for patients who were not receiving FML. Patients who
continued to have high proinﬂammatory protein expressions while
also suffering from lowered lacrimal gland production (based on
LYZ, PIP and PRR4) after the 3-week treatment, were likely to
experiencemore severe desiccating stress effects in the conjunctiva
if they were not treated with FML. Hence, in the desiccating stress,
the initial severity of the patient no longer matters as long as they
have been treated with FML prior to the desiccating stress. From
these results CST4 was most notable, since it could separate the
severe andmoderate patients in both baseline and after the 3-week
treatment period. Hence, in addition to providing information of
the severity of desiccating stress reaction, it again could tell us of
the severity of the dry eye, even after corticosteroid treatment.
CST4 has previously been connected to DED and meibomian gland
dysfunction, where it was notably reduced in comparison to control
samples [43].
These results were only applicable with conjunctival staining,
while corneal staining and conjunctival hyperemia did not display a
similar relationship with the proteomics. This could be due to the
V3 sampling/visit time point taking place immediately after the
desiccating stress, resulting in inconsistency between the clinical
and proteomic data. Following the development of clinical signs
and proteomics more closely, i.e., including more time points,
during the 24-h window after the desiccating stress could have
provided us with better understanding of the speed and timing of
stress effects in the ocular surface.
Small sample amount (1 ml/patient/time point) could be
considered as a limiting factor of this study. Due to the small
quantities of samples, it was not possible to carry out further
validation of the results, and the reproducibility of sample recovery
on 1 ml tear samples could not be fully conﬁrmed. Furthermore, due
to limitations in proteomic sample preparation, sensitivity, and
technological features of LC-MSTOF, we were unable to quantify
small proteins such as cytokines as well as some of the well-known
markers for dry eye, such asmatrixmetalloproteinase-9 (MMP9), in
this study. Improved results for MSTOF could potentially be ac-
quired by optimizing the digestion protocol to, e.g., MMP9, but this
would be likely to have negative effects on other proteins of anal-
ysis. The results presented in this study should be complemented
and validated by independent clinical studies using either immu-
noassays or targeted MS/MS approach.
The reasons why there were no statistically signiﬁcant results in
proteomic comparisons immediately after the desiccating stress
(V3) and after 24 h recovery time (V4) can only be speculated. The
J. N€attinen et al. / The Ocular Surface 16 (2018) 84e92 9124 h may not have been a sufﬁcient time for the effects of recovery
to occur. When C57BL/6 mice were exposed to desiccating stress,
tear volume and ocular surface parameters recovered within 2
weeks, while non-obese diabetic mice, which are known develop
spontaneous dry eye and other related conditions, did not show
signs of recovery during the study (1 month after the desiccating
stress was removed) [44]. Hence, considering the individual pro-
teomic proﬁles of severe-to-moderate dry eye patients and their
individual initial recovery patterns, it can be expected that more
uniform changes in proteomics can be seen only several days or
evenweeks later. Our results further highlight the value of tear ﬂuid
proteomics in DED and for the development of therapeutic options.
5. Conclusions
Our study identiﬁed several differentially expressed proteins
between the FML and PA treatments. Our results suggest that the
FML treatment reduces the inﬂammation more efﬁciently than PA
treatment during the 3-week period. In addition, the clinical signs
were examined together with the proteomic data, and we identi-
ﬁed several proteins that could be considered potential biomarkers.
These proteins could not only indicate the changes in clinical signs,
but in some cases, could also differentiate moderate and severe
DED patients. Further validation is needed to verify these
biomarkers.
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